Biovista has been selected as one of the top-20 AI Drug Development companies in a recent article in Forbes View the article here: https://www.forbes.com/sites/yiannismouratidis/2018/12/16/the-rising-star-companies-in-ai-drug-development/
Month: March 2019
Biovista signs EU-IMI2 research agreement to advance neurotoxicity de-risking in preclinical drug discovery
Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative (IMI). Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Together with EFPIA members … Read More